Rituximab Monotherapy for EBV-HLH and CAEBV

NCT05384743 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Secondary Hemophagocytic Lymphohistiocytosis
Chronic Active Epstein-Barr Virus Infection

Interventions

DRUG: Rituximab Monotherapy

Sponsor

Beijing Friendship Hospital